检索结果 - L. Austin Doyle

Refine Results
  1. 1
    A multidrug resistance transporter from human MCF-7 breast cancer cells

    A multidrug resistance transporter from human MCF-7 breast cancer cells 由 L. Austin Doyle, Weidong Yang, Lynne V. Abruzzo, Tammy Krogmann, Yongming Gao, Arun K. Rishi, Douglas D. Ross

    出版 1998
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  2. 2
    Skeletal muscle anabolism is a side effect of therapy with the MEK inhibitor: selumetinib in patients with cholangiocarcinoma

    Skeletal muscle anabolism is a side effect of therapy with the MEK inhibitor: selumetinib in patients with cholangiocarcinoma 由 Carla M. Prado, Tanios Bekaii‐Saab, L. Austin Doyle, Sharad Shrestha, Sunita Ghosh, Vickie E. Baracos, Michael B. Sawyer

    出版 2012
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  3. 3
    Targeted Morphoproteomic Profiling of Ewing's Sarcoma Treated with Insulin-Like Growth Factor 1 Receptor (IGF1R) Inhibitors: Response/Resistance Signatures

    Targeted Morphoproteomic Profiling of Ewing's Sarcoma Treated with Insulin-Like Growth Factor 1 Receptor (IGF1R) Inhibitors: Response/Resistance Signatures 由 Vivek Subbiah, Aung Naing, Robert Brown, Helen Chen, L. Austin Doyle, Patricia LoRusso, Robert S. Benjamin, Pete Anderson, Razelle Kurzrock

    出版 2011
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  4. 4
    Management of Metabolic Effects Associated With Anticancer Agents Targeting the PI3K-Akt-mTOR Pathway

    Management of Metabolic Effects Associated With Anticancer Agents Targeting the PI3K-Akt-mTOR Pathway 由 Naifa L. Busaidy, Azeez Farooki, Afshin Dowlati, John P. Perentesis, Janet Dancey, L. Austin Doyle, Joanna M. Brell, Lillian L. Siu

    出版 2012
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  5. 5
    Insulin growth factor receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with metastatic adrenocortical carcinoma

    Insulin growth factor receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with metastatic adrenocortical carcinoma 由 Aung Naing, Patricia LoRusso, Siqing Fu, David S. Hong, H. X. Chen, L. Austin Doyle, Alexandria T. Phan, Mouhammed Amir Habra, Razelle Kurzrock

    出版 2013
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  6. 6
    High-dose radiotherapy in trimodality treatment of Pancoast tumors results in high pathologic complete response rates and excellent long-term survival

    High-dose radiotherapy in trimodality treatment of Pancoast tumors results in high pathologic complete response rates and excellent long-term survival 由 King F. Kwong, Martin J. Edelman, Mohan Suntharalingam, Lindsay B. Cooper, Ziv Gamliel, W. Burrows, P Hausner, L. Austin Doyle, Mark J. Krasna

    出版 2005
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  7. 7
    Phase II study of cixutumumab in combination with temsirolimus in pediatric patients and young adults with recurrent or refractory sarcoma: A report from the children's oncology group

    Phase II study of cixutumumab in combination with temsirolimus in pediatric patients and young adults with recurrent or refractory sarcoma: A report from the children's oncology gr... 由 Lars M. Wagner, Maryam Fouladi, Atif Ahmed, Mark Krailo, Brenda J. Weigel, Steven G. DuBois, L. Austin Doyle, Helen Chen, Susan M. Blaney

    出版 2014
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  8. 8
    Insulin Growth Factor-Receptor (IGF-1R) Antibody Cixutumumab Combined with the mTOR Inhibitor Temsirolimus in Patients with Refractory Ewing's Sarcoma Family Tumors

    Insulin Growth Factor-Receptor (IGF-1R) Antibody Cixutumumab Combined with the mTOR Inhibitor Temsirolimus in Patients with Refractory Ewing's Sarcoma Family Tumors 由 Aung Naing, Patricia LoRusso, Siqing Fu, David S. Hong, Pete Anderson, Robert S. Benjamin, Joseph A. Ludwig, Helen X. Chen, L. Austin Doyle, Razelle Kurzrock

    出版 2012
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  9. 9
    Atypical Multidrug Resistance: Breast Cancer Resistance Protein Messenger RNA Expression in Mitoxantrone-Selected Cell Lines

    Atypical Multidrug Resistance: Breast Cancer Resistance Protein Messenger RNA Expression in Mitoxantrone-Selected Cell Lines 由 D D Ross, Weidong Yang, Lynne V. Abruzzo, William S. Dalton, E Schneider, Hermann Lage, Manfred Dietel, Lee M. Greenberger, Susan P.C. Cole, L. Austin Doyle

    出版 1999
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  10. 10
    Biomarker-driven phase 2 study of MK-2206 and selumetinib (AZD6244, ARRY-142886) in patients with colorectal cancer

    Biomarker-driven phase 2 study of MK-2206 and selumetinib (AZD6244, ARRY-142886) in patients with colorectal cancer 由 T. Khanh, Giovanna Speranza, Rachel Bishop, Sonny Khin, Larry Rubinstein, Robert J. Kinders, Manuel B. Datiles, Michelle Eugeni, Michael Lam, L. Austin Doyle, James H. Doroshow, Shivaani Kummar

    出版 2015
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  11. 11
    Temsirolimus Has Activity in Non–Mantle Cell Non-Hodgkin's Lymphoma Subtypes: The University of Chicago Phase II Consortium

    Temsirolimus Has Activity in Non–Mantle Cell Non-Hodgkin's Lymphoma Subtypes: The University of Chicago Phase II Consortium 由 Sonali M. Smith, Koen van Besien, Theodore Karrison, Janet Dancey, Peter McLaughlin, Anas Younes, Scott E. Smith, Patrick J. Stiff, Eric P. Lester, Sanjiv Modi, L. Austin Doyle, Everett E. Vokes, Barbara Pro

    出版 2010
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  12. 12
    Phase I Trial of Cixutumumab Combined with Temsirolimus in Patients with Advanced Cancer

    Phase I Trial of Cixutumumab Combined with Temsirolimus in Patients with Advanced Cancer 由 Aung Naing, Razelle Kurzrock, Angelika M. Burger, Sachin Gupta, Xiudong Lei, Naifa L. Busaidy, David S. Hong, Helen X. Chen, L. Austin Doyle, Lance K. Heilbrun, Eric Rohren, Chaan S. Ng, Chandtip Chandhasin, Patricia LoRusso

    出版 2011
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  13. 13
    A phase I trial of vertical inhibition of IGF signalling using cixutumumab, an anti-IGF-1R antibody, and selumetinib, an MEK 1/2 inhibitor, in advanced solid tumours

    A phase I trial of vertical inhibition of IGF signalling using cixutumumab, an anti-IGF-1R antibody, and selumetinib, an MEK 1/2 inhibitor, in advanced solid tumours 由 Breelyn A. Wilky, Michelle A. Rudek, Shabina Roohi Ahmed, Dan Laheru, David Cosgrove, Ross C. Donehower, Barry D. Nelkin, Douglas W. Ball, L. Austin Doyle, H Chen, X Ye, Graham Bigley, Chris Womack, Nilofer S. Azad

    出版 2014
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  14. 14
    Combination of Temsirolimus (CCI-779) with Chemoradiation in Newly Diagnosed Glioblastoma Multiforme (GBM) (NCCTG trial N027D) Is Associated with Increased Infectious Risks

    Combination of Temsirolimus (CCI-779) with Chemoradiation in Newly Diagnosed Glioblastoma Multiforme (GBM) (NCCTG trial N027D) Is Associated with Increased Infectious Risks 由 Jann N. Sarkaria, E. Galanis, Wenting Wu, Allan B. Dietz, Timothy J. Kaufmann, Michael P. Gustafson, Paul D. Brown, Joon H. Uhm, Ravi D. Rao, L. Austin Doyle, Caterina Giannini, Kurt A. Jaeckle, Jan C. Buckner

    出版 2010
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  15. 15
    A Phase I Study of Dinaciclib in Combination With MK‐2206 in Patients With Advanced Pancreatic Cancer

    A Phase I Study of Dinaciclib in Combination With MK‐2206 in Patients With Advanced Pancreatic Cancer 由 Adrian Murphy, Marianna Zahurak, Mirat Shah, Colin D. Weekes, Aaron R. Hansen, Lillian L. Siu, Anna Spreafico, Noelle K. LoConte, Nicole M. Anders, T. Miles, Michelle A. Rudek, L. Austin Doyle, Barry D. Nelkin, Anirban Maitra, Nilofer S. Azad

    出版 2020
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  16. 16
    Clinical activity of sequential flavopiridol, cytosine arabinoside, and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia

    Clinical activity of sequential flavopiridol, cytosine arabinoside, and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia 由 Judith E. Karp, Amanda L. Blackford, B. Douglas Smith, Katrina Alino, Amy Hatfield Seung, Javier Bolaños‐Meade, Jacqueline M. Greer, Hetty E. Carraway, Steven D. Gore, Richard J. Jones, Mark J. Levis, Michael A. McDevitt, L. Austin Doyle, James R. Wright

    出版 2009
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  17. 17
    Effect of Selumetinib and MK-2206 vs Oxaliplatin and Fluorouracil in Patients With Metastatic Pancreatic Cancer After Prior Therapy

    Effect of Selumetinib and MK-2206 vs Oxaliplatin and Fluorouracil in Patients With Metastatic Pancreatic Cancer After Prior Therapy 由 Vincent Chung, Shannon McDonough, Philip A. Philip, Dana B. Cardin, Andrea Wang‐Gillam, Laifong Hui, Mohamedtaki Abdulaziz Tejani, Tara Elisabeth Seery, Irene Dy, Tareq Al Baghdadi, Andrew Hendifar, L. Austin Doyle, Andrew M. Lowy, Katherine A. Guthrie, Charles D. Blanke, Howard S. Höchster

    出版 2016
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  18. 18
    Randomized phase II trial of cytosine arabinoside with and without the CHK1 inhibitor MK-8776 in relapsed and refractory acute myeloid leukemia

    Randomized phase II trial of cytosine arabinoside with and without the CHK1 inhibitor MK-8776 in relapsed and refractory acute myeloid leukemia 由 Jonathan Webster, Raoul Tibes, Larry Morris, Amanda L. Blackford, Mark R. Litzow, Mrinal M. Patnaik, Gary L. Rosner, Ivana Gojo, Robert J. Kinders, Lihua Wang, L. Austin Doyle, Catherine J. Huntoon, Larry M. Karnitz, Scott H. Kaufmann, Judith E. Karp, B. Douglas Smith

    出版 2017
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  19. 19
    Multi-Institutional Phase II Study of Selumetinib in Patients With Metastatic Biliary Cancers

    Multi-Institutional Phase II Study of Selumetinib in Patients With Metastatic Biliary Cancers 由 Tanios Bekaii‐Saab, Mitch A. Phelps, Xiaobai Li, Motoyasu Saji, Laura W. Goff, John Kauh, Bert H. O’Neil, Stephanie Balsom, Catherine Balint, R. Liersemann, Vasily Vasko, Mark Bloomston, W. Marsh, L. Austin Doyle, Gilian Ellison, Michael R. Grever, Matthew D. Ringel, Miguel A. Villalona‐Calero

    出版 2011
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  20. 20
    Phase 1 and pharmacokinetic study of bolus-infusion flavopiridol followed by cytosine arabinoside and mitoxantrone for acute leukemias

    Phase 1 and pharmacokinetic study of bolus-infusion flavopiridol followed by cytosine arabinoside and mitoxantrone for acute leukemias 由 Judith E. Karp, Benjamin D. Smith, Linda Resar, Jacqueline M. Greer, Amanda L. Blackford, Ming Zhao, Dwella Moton-Nelson, Katrina Alino, Mark J. Levis, Steven D. Gore, Biju Joseph, Hetty E. Carraway, Michael A. McDevitt, Lorena Bagain, Karen Mackey, Janet Briel, L. Austin Doyle, James R. Wright, Michelle A. Rudek

    出版 2011
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:

检索工具: